References
- Saavedra D, Vizcarra F. Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety. Leuk Lymphoma 2014 Jun 17. [Epub ahead of print]
- Eskazan AE, Elverdi T, Yalniz FF, et al. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia. Leuk Lymphoma 2014 May 6. [Epub ahead of print]
- Alwan AF, Matti BF, Naji AS, et al. Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back. Leuk Lymphoma 2014 Apr 22. [Epub ahead of print]
- Razmkhah F, Razavi M, Zaker F, et al. Hematologic and molecular responses to generic imatinib in patients with chronic myeloid leukemia. Lab Med 2010;41:547–550.
- Jawhari D, Alswisi M, Ghannam M. Bioavailability of a new generic formulation of imatinib mesylate 400mg tablets versus glivec in healthy male adult volunteers. J Bioequiv Availab 2011;3:161–164.
- Grillo D, Polla G, Vega D. Conformational polymorphism on imatinib mesylate: grinding effects. J Pharm Sci 2012;101:541–551.
- Khoshnaw MN, Francis B, Safar BM, et al. Cytogenetic response in chronic myeloid leukaemia patients treated with imatinib mesylate homolog-drugs: 6 year's transitional study. J Cancer Ther 2014;5: 453–459.